LSP Funds

Life Sciences Partners #publicequity seeks to invest in innovative publicly listed #healthcare companies EU/US. #EuronextAMS:LSP

[LSP Funds @LSP_PublicFund]

Is a #cure for #cancer close at hand? https://t.co/sj32K1BsXK #ASH17

[Evotec @Evotec]

What if you could boost development with limited capital investment – by reviewing and improving processes? Read @Labiotech_eu interview with Stephen East, VP Innovation Efficiency at @EvotecAG, and learn more https://t.co/dzCSHrvj7Y

[LifeSci Communications @LifeSciComms]

Starting off day 3 at #BIO2018 is Daniel de Boer, CEO of @ProQR, with Ryan Cross from @cenmag discussing ProQR’s development programs for #RareDisease including #EpidermolysisBullosa and #LebersCongenitalAmaurosis @RLCscienceboss @BIOCONVENTION

[LSP Funds @LSP_PublicFund]

Ablynx - BioCapital Company of the Year 2018
Ablynx NV CEO Edwin Moses sounds the gong, celebrating the company’s recent ‘BioCapital Company of the Year’ award.
https://t.co/KJVBBFdpZ7

[LSP Funds @LSP_PublicFund]

Another small but important step forward for #Argenx as its lead compound ARGX113 gets orphan drug status in Europe https://t.co/IuKXdmpygm

[LSP Funds @LSP_PublicFund]

argenx

[LSP Funds @LSP_PublicFund]

#Evotec creates the 'one stop shop' of drug discovery https://t.co/5XRRfN4r7m

[LSP Funds @LSP_PublicFund]

Kiadis now has the financial resources to bring this important treatment to the market https://t.co/ODZoPKimik

[PharmaLeaders @Pharma_Leaders]

Kiadis raises €23.4m to develop immunotherapy for GVHD https://t.co/ETFygnbIOR

[LSP Funds @LSP_PublicFund]

Additional data confirms the strong drug profile of MOR208 https://t.co/IRyFMT6IFZ

[Oncode Institute @oncodeinstitute]

René Kuijten, Hans Schikan and @bleeftink share their thoughts about #valorisation: scientific breakthroughs need to reach #patients. #Oncode #outsmartingcancer @HealthHolland @MinisterieEZK

[LSP Funds @LSP_PublicFund]

Congratulations to Edwin Moses and the rest of the Ablynx team https://t.co/eg4kAndVhX

[Reuters @Reuters]

Sanofi trumps Novo Nordisk with agreed 3.9 billion euros bid for Ablynx https://t.co/waXEhIHp88

[OptimumComms @OptimumComms]

Progressing #Alzheimers research. Dr Konrad Glund, CEO @ProbiodrugAG speaks to @ScripMikeWard @EBDgroup #BTS18 #JPM18

[LSP Funds @LSP_PublicFund]

A very interesting discussion on a very important topic https://t.co/OWKd0Fwev9

[Financial Times @FinancialTimes]

Did you know there are 50m people worldwide living with dementia? Here's how you can help fund vital research to stop or slow underlying diseases such as Alzheimer's with our seasonal appeal partner @ARUKnews https://t.co/3en2ibhclD #FTappeal

[LSP Funds @LSP_PublicFund]

Great innovation combined with real progress at FDA is accelerating drug and medical device development https://t.co/LbiGSG08e3

[OptimumComms @OptimumComms]

#LSP @LSP_PublicFund https://t.co/C0zuzDS529

[LSP Funds @LSP_PublicFund]

LSP closes second Health Economics Fund @LSP_PublicFund at $330m; https://t.co/NWwfgI9vSM

[LSP Funds @LSP_PublicFund]

ArgenX is changing the way autoimmune diseases will be treated in the future. excellent results for ARGX-113 https://t.co/rWJ42ztsfT

[Odi Bruckman @odibro]

$ARGX reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis https://t.co/1r1XOLGdO1

[LSP Funds @LSP_PublicFund]

The latest update on the @LSP_PublicFund is now available;
https://t.co/7U2f9MJ0lE

[LSP Funds @LSP_PublicFund]

The latest update on the LSP Life Sciences Fund is now available:
https://t.co/L9Bb02qyzv

[LSP Funds @LSP_PublicFund]

Great TEDX presentation in the future of regenerative medicine by @LSP_PublicFund partner Clemens van Blitterswijk
https://t.co/W2NWUvWaYe

[Evotec @Evotec]

We are working towards strengthening our #iPSC based drug discovery platform through substantial internal effort & external collaborations. Learn more at the webinar co-presented by Evotec and Newcells biotech in a few hours.
https://t.co/x8tfbFz9ww
@CHI_Healthtech